Embecta Corporation (EMBC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis ...

In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Sell rating on Embecta Corporation (EMBC – Research Report), ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 results. Read more here.

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ETCompany ParticipantsPravesh Khandelwal - VP of IRDev Kurdikar ...

Embecta reports fourth quarter earnings beating estimates, discontinues insulin patch program, and announces restructuring ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.